HC Wainwright & Co. Maintains Buy on Dare Bioscience, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Dare Bioscience (NASDAQ:DARE) but lowers the price target from $7 to $6.
November 10, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Dare Bioscience, indicating continued confidence in the company.
The lowered price target might initially seem negative, but the maintained 'Buy' rating indicates that the analyst still sees potential in the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100